These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25285304)

  • 1. Blood Pressure, Heart Rate, and CNS Stimulant Medication Use in Children with and without ADHD: Analysis of NHANES Data.
    Hailpern SM; Egan BM; Lewis KD; Wagner C; Shattat GF; Al Qaoud DI; Shatat IF
    Front Pediatr; 2014; 2():100. PubMed ID: 25285304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the effect of ADHD stimulant medication on heart rate and blood pressure in a community sample of children?
    St Amour MD; O'Leary DD; Cairney J; Wade TJ
    Can J Public Health; 2018 Jun; 109(3):395-400. PubMed ID: 29981090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attention deficit disorder, stimulant use, and childhood body mass index trajectory.
    Schwartz BS; Bailey-Davis L; Bandeen-Roche K; Pollak J; Hirsch AG; Nau C; Liu AY; Glass TA
    Pediatrics; 2014 Apr; 133(4):668-76. PubMed ID: 24639278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8-15 years: National Health and Nutrition Examination Survey 2001-2004.
    Byrd HC; Curtin C; Anderson SE
    Pediatr Obes; 2013 Dec; 8(6):445-53. PubMed ID: 23325553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Trends in the Diagnosis of Attention-Deficit/Hyperactivity Disorder and Stimulant Use in Preschool Children on Medicaid.
    Davis DW; Feygin Y; Creel L; Williams PG; Lohr WD; Jones VF; Le J; Pasquenza N; Ghosal S; Jawad K; Yan X; Liu G; McKinley S
    J Pediatr; 2019 Apr; 207():185-191.e1. PubMed ID: 30545564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attention deficit hyperactivity disorder: comorbidity and medication use.
    Kube DA; Petersen MC; Palmer FB
    Clin Pediatr (Phila); 2002 Sep; 41(7):461-9. PubMed ID: 12365307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study.
    Rose SR; Reeves G; Gut R; Germak J
    J Pediatr; 2015 Dec; 167(6):1389-96. PubMed ID: 26394822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suicidal ideation and attempts in the United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit/hyperactivity disorder.
    Siffel C; DerSarkissian M; Kponee-Shovein K; Spalding W; Gu YM; Cheng M; Duh MS
    J Affect Disord; 2020 Apr; 266():109-119. PubMed ID: 32063553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. School board survey of attention deficit/hyperactivity disorder: Prevalence of diagnosis and stimulant medication therapy.
    Sgro M; Roberts W; Grossman S; Barozzino T
    Paediatr Child Health; 2000 Jan; 5(1):19-23. PubMed ID: 20107591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of and Factors Associated With Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder.
    Wei YJ; Zhu Y; Liu W; Bussing R; Winterstein AG
    JAMA Netw Open; 2018 Aug; 1(4):e181152. PubMed ID: 30646105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic profile and behavioral characteristics during induction of anesthesia in pediatric patients with attention deficit hyperactivity disorder.
    Cartabuke RS; Tobias JD; Rice J; Tumin D
    Paediatr Anaesth; 2017 Apr; 27(4):417-424. PubMed ID: 28181385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and Management of Elevated Blood Pressure in Children and Adolescents with Attention Deficit Hyperactivity Disorder.
    Yamaguchi I; Hanevold C
    Curr Hypertens Rep; 2019 Jun; 21(8):60. PubMed ID: 31218513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of medication by young people with attention-deficit/hyperactivity disorder.
    Sawyer MG; Rey JM; Graetz BW; Clark JJ; Baghurst PA
    Med J Aust; 2002 Jul; 177(1):21-5. PubMed ID: 12088474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physician perceptions of the use of medications for attention deficit hyperactivity disorder.
    Stockl KM; Hughes TE; Jarrar MA; Secnik K; Perwien AR
    J Manag Care Pharm; 2003; 9(5):416-23. PubMed ID: 14613439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Palli SR; Kamble PS; Chen H; Aparasu RR
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):139-48. PubMed ID: 22364400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children.
    Levin H; Hanten G; Max J; Li X; Swank P; Ewing-Cobbs L; Dennis M; Menefee DS; Schachar R
    J Dev Behav Pediatr; 2007 Apr; 28(2):108-18. PubMed ID: 17435461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.